ReviewCancers2021
Surgery after Induction Targeted Therapy and Immunotherapy for Lung Cancer.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Feasibility and oncologic outcomes of minimally invasive surgery after induction chemoimmunotherapy for non-small cell lung cancer.JTCVS open · 2026Article
- A SEER derived prognostic nomogram identifies stage IV metastatic lung squamous cell carcinoma patients who may benefit from primary tumor resection.Discover oncology · 2026Article
- Surgery after neoadjuvant therapy in patients with resectable stage IIIB/N2 non-small cell lung cancer.BMC pulmonary medicine · 2025Article
- Methylation of RBM39 by PRMT6 enhances resistance to Indisulam in non-small cell lung cancer by promoting alternative splicing of proto-oncogenes.PLoS biology · 2025Article
- Two vs three cycles of neoadjuvant immunochemotherapy for resectable non-small-cell lung cancer: a real-world population-based study.Frontiers in immunology · 2025Article
- Surgical treatment of IIIb (N2), ROS1(+) non-small cell lung cancer after neoadjuvant chemotherapy combined with targeted therapy: a case report.AME case reports · 2025Article
- Efficacy of Neoadjuvant Therapy for ROS1-Positive Locally-Advanced Lung Adenocarcinoma: A Case Report.The American journal of case reports · 2024Article
- Radical resection in a patient with stage IIIA non-small cell lung cancer with theTranslational lung cancer research · 2024Article
- Neoadjuvant therapy and sleeve lobectomy for locally advanced non-small cell lung cancer: morbidity and survival balancing.Journal of thoracic disease · 2024Article
- Review
- The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis.JTO clinical and research reports · 2024Article
- A new, potential and safe neoadjuvant therapy strategy in epidermal growth factor receptor mutation-positive resectable non-small-cell lung cancer-targeted therapy: a retrospective study.Frontiers in oncology · 2024Article
- Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.Frontiers in immunology · 2024Review
- Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges.Nature reviews. Clinical oncology · 2023Review
- ZFP36 loss-mediated BARX1 stabilization promotes malignant phenotypes by transactivating master oncogenes in NSCLC.Cell death & disease · 2023Article
- Review
- The Role of Surgery in Lung Cancer Treatment: Present Indications and Future Perspectives-State of the Art.Cancers · 2021Review
- Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multimodality therapy for locally advanced non-small cell lung cancer (NSCLC) is a complex and controversial issue, especially regarding optimal treatment regimens for patients with ipsilateral positive mediastinal nodes (N2 disease). Many trials investigating neoadjuvant immunotherapy and targeted therapy in this subpopulation have shown promising results, although concerns have risen regarding surgical feasibility. A thorough literature review was performed, analyzing all recent studies regarding surgical morbidity and mortality. Despite the fact that two major trials investigating this subject were terminated early, the overall consensus is that surgical management seems feasible. However, dissection of hilar vessels may be challenging due to hilar fibrosis. Further research is necessary to identify the role of surgery in these multimodality treatment regimens, and to define matters such as the optimal treatment regimen, the dosage of the different agents used, the interval between induction therapy and surgery, and the role of adjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.